Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396448 · ClinicalTrials.gov registry record · Phase 3
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,253
- Enrollment target
NCT00396448: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00396448 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,253 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00396448, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,253 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
Interventions
- DRUG Placebo
- DRUG CP-945,598 Treatment B
- DRUG CP-945,598 Treatment A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,253 participants |
| Start Date | 2007-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Why NCT00396448 stopped before completion
NCT00396448 is an interventional study that assigns participants to a tested intervention. Its 1,253 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00396448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00396448 about?
NCT00396448 is a clinical study titled "Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.". The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
What is the current status of trial NCT00396448?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,253 participants. The study started on 2007-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00396448?
The interventions under investigation include: Placebo (DRUG), CP-945,598 Treatment B (DRUG), CP-945,598 Treatment A (DRUG).
Who is sponsoring clinical trial NCT00396448?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00396448's enrollment target sits among peer trials
1,253 206th of 2000 higher than 1,795 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia